EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

De Novo EGFR ‐ ALK and EGFR ‐ ROS1 Co‐Mutations in NSCLC : Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis

Lili Shen, Hongyu Deng, Wei Liao, Qiang Gu, Lingling Ma, Qingming Jiang, Kaihua Liu iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.71084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Lili Shen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Chongqing University Cancer Hospital, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Anaplastic Lymphoma Kinase, Mutation. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

De novo epidermal growth factor receptor‐anaplastic lymphoma kinase ( EGFR ‐ ALK ) and EGFR ‐ROS proto‐oncogene 1 ( EGFR ‐ ROS1 ) co‐mutations in non‐small‐cell lung cancer (NSCLC), conditions traditionally considered mutually exclusive. We present the first large‑scale analysis of their clinical and genomic profiles.

Methods

We identified 26 patients with EGFR ‐ ALK ( n = 20) or EGFR ‐ ROS1 ( n = 6) co‐mutations from two institutions and compared them with cohorts of EGFR ‐only, ALK ‐only, ROS1 ‐only, and non‐co‐mutated (NC) controls. Additionally, we validated findings in 66 published co‐mutation cases through a literature review (2010–2023).

Results

The co‐mutation frequencies were 0.36% for EGFR ‐ ALK and 0.11% for EGFR ‐ ROS1 . EGFR ‐ ALK co‐mutations were more commonly diagnosed at earlier stages (50.0% stage 0‐II vs. 22.6% in ALK ‐only, p = 0.03). Patients with EGFR ‐ ALK co‐mutations were older than those with ALK ‐only mutations (≥ 60 years: 60.0% vs. 24.5% in ALK ‐only, p = 0.01), a trend validated in external pooled cases (51.9% vs. 24.5%, p = 0.01). All EGFR ‐ ROS1 cases were never‐smokers and predominantly female (66.7%), a trend consistent with external pooled cases. Co‐mutated tumors were enriched for EGFR exon 19 deletion (19del, 60.0% vs. 42.2% EGFR ‐only) and depleted for L858R. Additionally, 80.0% of EGFR ‐ ALK cases harbored the EML4 ‐ ALK V3. Non‐smokers exhibited superior overall survival (OS) in both cases (internal p = 0.002, external pooled cases p = 0.03). Among 10 advanced‐stage patients with sufficient clinical follow‐up, two had received dual‐targeted TKI therapies. Both patients tolerated dual‐targeted TKI therapies well, with one requiring dose adjustment due to initial toxicity and subsequently achieving an overall survival exceeding 51 months; however, limited sample size precludes definitive conclusions regarding efficacy.

Conclusion

De novo co‐mutations represent a distinct NSCLC subset with unique clinical and genomic features, and dual‐targeted therapy shows promise as a strategy that warrants evaluation in prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAnaplastic Lymphoma KinaseMutationProtein-Tyrosine KinasesProto-Oncogene ProteinsOncogene Proteins, FusionHumansErbB ReceptorsFemaleMiddle AgedMaleProto-Oncogene MasAgedRetrospective StudiesAdultTreatment OutcomeNeoplasm StagingAged, 80 and over

Stichwörter der Autor:innen

EGFR‐ALK co‐mutationEGFR‐ROS1 co‐mutationde novo mutationnon‐small cell lung cancertargeted therapy

Substanzen

ROS1 protein, humanErbB ReceptorsProto-Oncogene MasMAS1 protein, humanAnaplastic Lymphoma KinaseEGFR protein, humanProtein-Tyrosine KinasesALK protein, humanProto-Oncogene ProteinsOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Department of Pathology, Chongqing University Cancer Hospital, China.
  • Chongqing Key Laboratory for Intelligent Oncology in Breast Cancer, Chongqing University Cancer Hospital, China.
  • The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China.
  • Institute of Cardiovascular Surgery, Xin Qiao Hospital, Second Affiliated Hospital of the Army Military Medical University, Chongqing, China.
  • Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.

ORCID-Profile: Kaihua Liu

Zitieren

APA

Shen, L., Deng, H., Liao, W., Gu, Q., Ma, L., Jiang, Q., & Liu, K. (2025). De Novo EGFR ‐ ALK and EGFR ‐ ROS1 Co‐Mutations in NSCLC : Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis. Cancer Medicine. https://doi.org/10.1002/cam4.71084

Vancouver

Shen L, Deng H, Liao W, Gu Q, Ma L, Jiang Q, et al. De Novo EGFR ‐ ALK and EGFR ‐ ROS1 Co‐Mutations in NSCLC : Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis. Cancer Medicine. 2025. doi:10.1002/cam4.71084

BibTeX
@article{Shen2025,
  author = {Shen, Lili and Deng, Hongyu and Liao, Wei and Gu, Qiang and Ma, Lingling and Jiang, Qingming and Liu, Kaihua},
  title = {De Novo EGFR ‐ ALK and EGFR ‐ ROS1 Co‐Mutations in NSCLC : Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71084}
}
Kostenlos starten →